2. GPCR/G Protein Immunology/Inflammation
  3. CXCR
  4. Ulocuplumab

Ulocuplumab  (Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody)

Cat. No.: HY-P99272 Purity: 99.90%
COA

Molarity Calculator

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.

For research use only. We do not sell to patients.

Ulocuplumab Chemical Structure

Ulocuplumab Chemical Structure

CAS No. : 1375830-34-4

Size Price Stock Quantity
1 mg USD 300 In-stock
5 mg USD 780 In-stock
10 mg USD 1250 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Ulocuplumab Related Antibodies

Top Publications Citing Use of Products

View All CXCR Isoform Specific Products:

View All Isoforms

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models[1][2].

IC50 & Target[1][2]

CXCR4

 

In Vitro

Ulocuplumab (0-100 μM; 48 h) lacks antibody dependent cellular cytotoxicity (ADCC) or complement (CDC) activity, but also induces apoptosis mediated by CXCR4 binding in Ramos cells and CLL/cancer cell lines, also shows pro-apoptotic in primary leukemia cells from CLL patients[1].
Ulocuplumab (0.2 μM and 2 μM; 15 s) inhibits F-actin polymerization and reduces the peak response to CXCL12, and also (20 nM-2 μM; 1 h) inhibits cell migration[1].
Ulocuplumab (200 nM; 6 h) leads to induction of programmed cell death (PCD) is caspase independent[1].
Ulocuplumab (10 μg/mL; 4 h) induces cell death via production of reactive oxygen species (ROS) in CLL cells[1].
Ulocuplumab inhibits CXCL12-induced calcium flux with an EC50 value of 10 nM in Ramos[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ulocuplumab Related Antibodies

Apoptosis Analysis[1]

Cell Line: Ramos cells and primary leukemia cells (from CLL patients)
Concentration: 0-100 μM
Incubation Time: 48 hours
Result: Induced apoptosis in Ramos cells with an IC50 value of 1.9 nM and showed pro-apoptotic with an IC50 value of 12.43 nM in primary leukemia cells from CLL patients.
In Vivo

Ulocuplumab (3-30 mg/kg; i.p.; every 3-4 days for 5 doses; 65 days in total) inhibits tumor growth of multiple myeloma xenograft models in mice, including Ramos B cells, HL-60 cells, MOLP-8 cells, Nomo-1 cells, and JJN-3R cells models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Severe combined immunodeficient (SCID) mice of AML model (MOLP-8 cells)[1]
Dosage: 3-30 mg/kg
Administration: Intraperitoneal injection; every 3-4 days for 5 doses; last for 65 days
Result: Significantly delayed mean tumor growth by 66% and 56% when compared with isotype control on day 25.
Clinical Trial
Molecular Weight

146.2 (kDa)

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Ulocuplumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 99.90%

COA (232 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ulocuplumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ulocuplumab1375830-34-4BMS 936564 MDX 1338 Anti-Human CXCR4 Recombinant AntibodyBMS936564BMS-936564MDX1338MDX 1338MDX-1338CXCRCXC chemokine receptorsC-X-C motif chemokine receptorsIgG4chronic lymphocytic leukemiaCLLcell migrationRamos B cellsHL-60 cellsMOLP-8 cellsNomo-1 cellsJJN-3R cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ulocuplumab
Cat. No.:
HY-P99272
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.